Non-Small-Cell Lung Cancer
Conditions
Keywords
NSCLC, apatinib, phase II, lung, cancer
Brief summary
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.
Interventions
DRUGapatinib
Apatinib 750 mg p.o. once daily
DRUGplacebo
placebo p.o. once daily
Sponsors
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* ≥ 18 and ≤ 70 years of age * Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer. * At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan) * Have failed for 2 lines of chemotherapy including EGFR-TKI. * ECOG performance scale 0 - 1. * Life expectancy of more than 3 months. * Duration from the last therapy is more than 6 weeks for nitroso or mitomycin * More than 4 weeks after operation or radiotherapy * More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors * Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10\^9/L, neutrophils ≥ 1.5×10\^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, * signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
Exclusion criteria
* Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer) * Pregnant or breastfeeding women * Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure * Any factors that influence the usage of oral administration * PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation. * Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3). * Long-term untreated wounds or fractures. * Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc. * Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed. * Abuse of alcohol or drugs * Less than 4 weeks from the last clinical trial * Treatment with VEGFR, PDGFR, sSRC-TKI before. * History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival safety | 8 weeks |
| DCR(Disease control rate) | 8 weeks |
| ORR(objective response rate) | 8 weeks |
| QoL(quality of life) | 8 weeks |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 8 weeks |
Countries
China
Outcome results
None listed